Vasomedical reports Q3 results

Vasomedical reported Q3 revenue of $10.8M, down 12.9% year-over-year. Net income from continuing operations fell to $568K from $1.6M in the same period last year. Adjusted EBITDA also decreased to $691K from $1.3M. The company had $53.3M in cash and equivalents.

Original reporting
Published Nov 16, 2026, 7:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 7:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$VASO
Bearish
medium confidence
Mentioned
$VASO
Relevance
6/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$VASOBearishMed
01

Why it matters

Traders will likely focus on the direction of revenue and adjusted EBITDA versus expectations, and whether cash levels provide enough runway for continued operations or investment.

02

Market read

A quarterly earnings release with multiple year-over-year deteriorations can drive near-term repricing, especially for smaller-cap healthcare names.

03

What to watch

The excerpt lacks guidance, segment detail, and any restructuring or non-recurring items, which could materially change how traders interpret the year-over-year declines.

Relevance 6/10Novelty 6/10Timing: after-hours/next-session reaction to the Q3 earnings release

Background

The piece is a Seeking Alpha writeup of Vasomedical’s Q3 results, citing key income statement and cash figures from the company’s press release.

Company-level read

Ticker impact

$VASOBearishMedium confidence
Context

Vasomedical (VASO) reported Q3 revenue of $10.8M, down 12.9% Y/Y, with continuing-ops net income of $568k versus $1.6M a year ago.

Expected impact

Likely downside bias as investors weigh weaker top-line and profitability versus expectations.

Evidence & confidence

The article provides multiple year-over-year deteriorations (revenue, net income, adjusted EBITDA) but no forward guidance or one-off explanations, limiting conviction on magnitude of the move.

Market effects

Limited read-through; this is a single-company earnings print with no sector-wide catalyst described.

No specific regional macro or cross-border linkage mentioned.

No global supply, regulation, or cross-market driver cited.

Counterpoint

If the company’s cash position ($53.3M) is improving or burn is controlled, the market may treat the earnings weakness as temporary and focus on liquidity runway.

Key entities

  • Vasomedical

    US-listed medical device company reporting Q3 results with declining revenue and profitability year over year.

Related articles

$VASOMed

VASO Corp (VASO): Completion of Acquisition or Disposition of Assets

VASO Corp (VASO) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 1.01. Entry into a Material Definitive Agreement. On July 31, 2026, Vaso Corporation (“Vaso”), VasoTechnology, Inc., a Delaware corporation and wholly owned subsidiary of Vaso (“VasoTech”), NetWolves Network Services LLC, a Florida limited liability company and wholly owned

$JDMed

What JD.com (JD) Said on Its Q3 Earnings Call

JD.com reported Q3 earnings, noting a 50% YoY reduction in food delivery losses and 16.1% revenue growth in JD Logistics. AI investments and international expansion were highlighted, with plans to reduce food delivery investments in 2027. JD Retail aims for high single-digit margins long-term. The company closed its CECONOMY acquisition and saw Joybuy revenue grow 35% QoQ. Annual active users exceeded 750 million, with strong free cash flow growth.

$ONEWMed

OneWater Marine Q4 Earnings Call Highlights

OneWater Marine reported Q4 results with $54M in cash, $58M in liquidity, and debt reduced to $342M. Net leverage improved to 3.8x EBITDA. The company projected 2027 revenue of $1.78B-$1.88B and adjusted EBITDA of $80M-$95M. Fort Lauderdale Boat Show sales were slightly higher in units but lower in dollars. Pre-owned boat sourcing remains challenging, supporting price stability.

$SMWBMed

What Similarweb (SMWB) Said on Its Q3 Earnings Call

Similarweb (SMWB) reported Q3 earnings, noting a 6% YoY increase in customers spending over $100k ARR and a 27% rise in their average account value. The company raised its 2026 revenue forecast to $318M-$320M and expects Q4 revenue of $83.9M-$85.9M. Similarweb is seeing growth in AI-related products and partnerships, like a multiyear deal with NIQ. No single customer represents over 10% of revenue, and the company has multiple large, multiyear engagements.

$NXNTMedAI 8/10

Nexscient Reports Third Quarter 2026 Results

Nexscient, Inc. (NXNT) filed an SEC Form 8-K — Regulation FD Disclosure. EXHIBIT 99.1 Nexscient Reports Third Quarter 2026 Results; Revenue Rises Sequentially as Gross Margin Expands to Over 40% Nine-Month Pro Forma Revenue of $2.96 Million, Up 65% Year over Year LOS ANGELES / NOVEMBER 17, 2026 / ACCESSWIRE — Nexscient, Inc. (OTCQB: NXNT) (“Nexscient”